



NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE: REAL-WORLD APPLICATION OF NEW GUIDELINES AND TREATMENT ADVANCES

REFERENCES / MODULE 1

1. Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary. *Clin Infect Dis*. 2020;71(4):e1-e36.
2. Hwang JA, Kim S, Jo KW, Shim TS. Natural history of *Mycobacterium avium* complex lung disease in untreated patients with stable course. *Eur Respir J*. 2017;49(3):1600537. doi:10.1183/13993003.00537-2016
3. Kwon BS, Lee JH, Koh Y, et al. The natural history of non-cavitary nodular bronchiectatic *Mycobacterium avium* complex lung disease. *Respir Med*. 2019;150:45-50.
4. Moon SM, Jhun BW, Baek SY, et al. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. *Respir Med*. 2019;151:1-7.
5. Huh HJ, Kim SY, Shim HJ, et al. GenoType NTM-DR performance evaluation for identification of *Mycobacterium avium* complex and *Mycobacterium abscessus* and determination of clarithromycin and amikacin resistance. *J Clin Microbiol*. 2019;57(8). doi:10.1128/JCM.00516-19.
6. Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary *Mycobacterium avium*-intracellulare complex disease. *J Antimicrob Chemother*. 2017;72(suppl_2):i3-i19.
7. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary *Mycobacterium avium* complex disease. *Respir Med*. 2007;101(1):130-138.
8. Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by *Mycobacterium avium* complex (CONVERT). A prospective, open-label, randomized study. *Am J Respir Crit Care Med*. 2018;198(12):1559-1569.
9. Wallace RJ, Jr., Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. *Chest*. 2014;146(2):276-282.
10. Jeong BH, Jeon K, Park HY, et al. Intermittent antibiotic therapy for nodular bronchiectatic *Mycobacterium avium* complex lung disease. *Am J Respir Crit Care Med*. 2015;191(1):96-103.
11. Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of *Mycobacterium avium* complex lung disease. *Am J Respir Crit Care Med*. 2006;173(11):1283-1289.
12. Kadota JI, Kurashima A, Suzuki K. The clinical efficacy of a clarithromycin-based regimen for *Mycobacterium avium* complex disease: A nationwide post-marketing study. *J Infect Chemother*. 2017;23(5):293-300.
13. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J, Nienhaus A. Microbiological and clinical outcomes of treating non-mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: A systematic review and meta-analysis. *Chest*. 2017;152(1):120-142.
14. Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. *Eur Respir J*. 2013;42(6):1604-1613.
15. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of *Mycobacterium massiliense* from *Mycobacterium abscessus*. *Am J Respir Crit Care Med*. 2011;183(3):405-410.
16. Novosad SA, Beekmann SE, Polgreen PM, Mackey K, Winthrop KL. Treatment of *Mycobacterium abscessus* Infection. *Emerg Infect Dis*. 2016;22(3):511-514.